Can GLP-1s Help Before Prediabetes Shows?

What "Before Prediabetes" Actually Means

A person can carry significant metabolic risk without meeting the laboratory cutoffs for prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7% to 6.4%). The question here targets people whose blood sugar numbers still read as "normal" but whose body composition, insulin levels, or inflammatory markers already signal trouble. This is a real clinical population, not a hypothetical one.

Insulin resistance typically develops years before fasting glucose rises enough to trigger a prediabetes diagnosis. A 2012 analysis published in The Lancet estimated that beta-cell function is already reduced by roughly 50% by the time fasting glucose crosses the 100 mg/dL threshold [1]. Hyperinsulinemia, visceral adiposity, elevated triglycerides, and low HDL cholesterol often appear first. The Diabetes Prevention Program (DPP) demonstrated that lifestyle modification reduced type 2 diabetes incidence by 58% in prediabetic adults over 2.8 years [2]. But that trial started at the prediabetes stage. The logical question is whether intervening even earlier, with pharmacotherapy, could shift the trajectory further upstream.

GLP-1 receptor agonists do not require a diabetes or prediabetes diagnosis for prescription. Semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition [3]. That approval covers patients regardless of glycemic status.

The STEP Program: Weight Loss in People Without Diabetes

The STEP 1 trial (N=1,961) enrolled adults with a BMI of 30 or greater (or 27 or greater with a comorbidity) and excluded anyone with diabetes. At 68 weeks, participants on semaglutide 2.4 mg lost a mean of 14.9% of body weight compared with 2.4% in the placebo arm [4]. That is a clinically meaningful reduction. But weight was not the only metric that moved.

Fasting plasma glucose decreased by 4.7 mg/dL more in the semaglutide group than placebo, and HbA1c dropped by 0.24 percentage points more [4]. In a population whose average baseline HbA1c was already in the normal range (approximately 5.3% to 5.4%), those reductions suggest genuine improvement in glucose metabolism, not just weight-driven noise. Fasting insulin levels fell by 35.1% versus 5.0% in placebo, a gap that reflects reduced insulin resistance at the tissue level [4].

STEP 3 (N=611) combined semaglutide 2.4 mg with intensive behavioral therapy. Mean weight loss hit 16.0% at 68 weeks [5]. Participants in this arm also showed improvements in waist circumference (a proxy for visceral fat), C-reactive protein (an inflammatory marker), and systolic blood pressure. None of these participants had diabetes at enrollment.

Short version: the drug works on the metabolic parameters that precede prediabetes, not just on body weight.

Tirzepatide: Dual-Action Evidence From SURMOUNT-1

Tirzepatide activates both the GLP-1 and GIP receptors. SURMOUNT-1 (N=2,539) enrolled adults with obesity or overweight (with at least one comorbidity) who did not have diabetes [6]. At 72 weeks, weight loss ranged from 15.0% (5 mg dose) to 20.9% (15 mg dose), with the highest-dose group reaching 22.5% in a treatment-estimand analysis [6].

Glycemic parameters improved across every dose tier. Fasting glucose dropped by 6.4 to 10.0 mg/dL from a baseline mean of approximately 96 mg/dL. HbA1c decreased by 0.3 to 0.5 percentage points from a baseline mean of 5.5% [6]. Those are not trivial shifts. A 0.5-point HbA1c reduction in someone sitting at 5.5% pushes them to 5.0%, well into the normal range and further from the 5.7% prediabetes boundary.

Triglycerides fell by 20 to 30%, and systolic blood pressure decreased by 6 to 9 mmHg [6]. The metabolic syndrome components that typically cluster before glucose impairment appeared improved in a dose-dependent pattern. SURMOUNT-2 later confirmed tirzepatide's glucose-lowering effect in people who already had type 2 diabetes [7], but SURMOUNT-1 is the dataset that matters for the "before prediabetes" question.

The SCALE Trial: Liraglutide and Prediabetes Regression

The SCALE Obesity and Prediabetes trial provides the most direct evidence for GLP-1 receptor agonists preventing diabetes. This 3-year study (N=2,254) enrolled adults with obesity and prediabetes, then randomized them to liraglutide 3.0 mg (Saxenda) or placebo [8].

Results were striking. Liraglutide reduced the incidence of new-onset type 2 diabetes by 79% compared with placebo over 160 weeks (HR 0.21; 95% CI 0.13 to 0.34) [8]. The proportion of participants who reverted from prediabetes to normoglycemia was 66% in the liraglutide group versus 36% in placebo at week 160 [8]. Weight loss was 6.1% with liraglutide versus 1.9% with placebo.

"The SCALE data showed that sustained GLP-1 receptor agonist treatment can fundamentally alter the glycemic trajectory in at-risk individuals," noted Dr. John Wilding, Professor of Medicine at the University of Liverpool and co-author of the STEP 1 trial [9].

This trial enrolled people with prediabetes, not normoglycemia. But the mechanism of action does not switch on at a glucose threshold. GLP-1 receptor agonists enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic signaling [10]. Those effects operate on a continuum.

SELECT: Cardiovascular Protection Independent of Diabetes Status

The SELECT trial (N=17,604) tested semaglutide 2.4 mg against placebo in adults with established cardiovascular disease, a BMI of 27 or greater, and no diabetes [11]. Over a median follow-up of 39.8 months, semaglutide reduced the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [11].

This was the first trial to demonstrate cardiovascular risk reduction with a GLP-1 receptor agonist in a non-diabetic population. The result mattered because it separated the drug's metabolic and cardiovascular benefits from its glucose-lowering effect. Participants' mean baseline HbA1c was 5.8%, placing many in the prediabetic range but not all. The cardiovascular benefit applied across the glycemic spectrum [11].

"SELECT proved that the benefits of GLP-1 receptor agonists extend beyond glucose control. We are looking at a drug class that modifies cardiovascular risk through weight loss, anti-inflammatory effects, and direct vascular mechanisms," stated Dr. A. Michael Lincoff, lead investigator of SELECT and Vice Chairman of Cardiovascular Medicine at the Cleveland Clinic [12].

C-reactive protein, a systemic inflammatory marker, decreased by 37.2% in the semaglutide group at 104 weeks [11]. Inflammation is an early driver of atherosclerosis and metabolic dysfunction. Reducing it before glucose dysregulation appears could, in theory, break the sequence that leads from obesity to prediabetes to diabetes.

Insulin Resistance: The Upstream Target

The core question is whether GLP-1 receptor agonists act on the pathophysiology that precedes prediabetes. The answer, based on available data, is yes. Insulin resistance is measurable long before glucose levels rise.

The homeostatic model assessment of insulin resistance (HOMA-IR) quantifies how much insulin the pancreas must produce to maintain normal fasting glucose. A HOMA-IR above 2.5 is commonly used to define insulin resistance in research settings [13]. Many people with obesity carry HOMA-IR values of 3.0 to 6.0 while still maintaining "normal" fasting glucose through compensatory hyperinsulinemia.

In STEP 1, semaglutide 2.4 mg reduced HOMA-IR by approximately 40% from baseline [4]. SURMOUNT-1 showed similar reductions with tirzepatide across all dose groups [6]. These reductions are consistent with the known effects of weight loss on hepatic and peripheral insulin sensitivity, but they also reflect direct GLP-1 receptor-mediated improvements in beta-cell function. GLP-1 receptor agonists increase first-phase insulin secretion and restore the incretin effect, both of which deteriorate during the progression toward diabetes [10].

A 2023 post-hoc analysis of the STEP program published in Diabetes Care found that participants with higher baseline insulin resistance derived greater metabolic benefit from semaglutide treatment, even when their HbA1c was below 5.7% at enrollment [14]. The drug was not just preventing weight gain. It was correcting a metabolic defect already in progress.

What the Guidelines Say Right Now

The American Diabetes Association (ADA) 2024 Standards of Care recommend pharmacotherapy for obesity in adults with a BMI of 30 or greater, or 27 or greater with comorbidities, when lifestyle modifications alone are insufficient [15]. The ADA also recommends screening for prediabetes and type 2 diabetes in all adults with overweight or obesity, starting at age 35 [15].

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity lists semaglutide 2.4 mg and tirzepatide as first-line pharmacotherapy options [16]. The guideline does not restrict these medications to patients with glycemic abnormalities.

No guideline currently recommends GLP-1 receptor agonists specifically for "pre-prediabetes prevention" as a named indication. The clinical framing is weight management with cardiometabolic risk reduction. But the practical effect is the same: a person with a BMI of 32 and insulin resistance who receives semaglutide for weight management is also receiving a drug that lowers their fasting glucose, fasting insulin, HbA1c, triglycerides, and inflammatory markers. The metabolic benefit is embedded in the weight management indication.

Risks and Limitations of Early Intervention

GLP-1 receptor agonists are not metabolically benign. Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) occur in 40 to 70% of patients during dose titration [4][6]. Most side effects are mild to moderate and diminish over time, but they are real enough to cause treatment discontinuation in 4 to 7% of trial participants [4].

Pancreatitis risk has been a long-standing concern. A 2023 meta-analysis in The Lancet Diabetes & Endocrinology covering over 60,000 patients across GLP-1 receptor agonist trials found no statistically significant increase in acute pancreatitis risk (OR 1.02; 95% CI 0.78 to 1.34) [17]. The signal is reassuring but not zero, and patients with a personal history of pancreatitis should discuss this with their prescribing clinician.

Cost is a barrier. Without insurance coverage, semaglutide 2.4 mg (Wegovy) costs approximately $1,300 per month, and tirzepatide (Zepbound) sits in a similar range [3]. Insurance coverage for obesity pharmacotherapy remains inconsistent, and prescribing GLP-1 receptor agonists to someone with normal blood sugar may face additional coverage hurdles.

Weight regain after discontinuation is well-documented. The STEP 1 extension trial showed that participants regained approximately two-thirds of lost weight within one year of stopping semaglutide [18]. This means that any metabolic benefits of early treatment likely depend on sustained therapy, not a short course.

Who Might Benefit Most From Early GLP-1 Treatment

Not every person with a normal HbA1c needs a GLP-1 receptor agonist. The strongest case for early intervention exists in adults who meet all of the following: BMI of 30 or greater (or 27 or greater with cardiometabolic risk factors), fasting insulin or HOMA-IR in the insulin-resistant range, family history of type 2 diabetes, and a pattern of progressive weight gain despite lifestyle efforts.

A practical clinical approach might include checking fasting insulin and HOMA-IR alongside standard glucose screening. If fasting glucose is 92 mg/dL but fasting insulin is 22 mIU/L (HOMA-IR approximately 5.0), that person has compensated insulin resistance. Their beta cells are working overtime. Without intervention, fasting glucose will likely cross the prediabetic threshold within 3 to 5 years based on longitudinal data from the Whitehall II cohort study [19].

For these patients, GLP-1 receptor agonists offer a pharmacological option that targets the upstream pathology. Lifestyle modification remains the foundation. Diet and exercise improve insulin sensitivity independently of weight loss. But for the subset of patients who have been unable to achieve or maintain meaningful weight loss through lifestyle alone, GLP-1 receptor agonists provide a mechanism-based treatment that addresses insulin resistance, visceral adiposity, and systemic inflammation simultaneously.

The bottom line: GLP-1 receptor agonists can reduce the metabolic risk factors that lead to prediabetes, even when blood glucose is still normal. Prescribing decisions should be individualized, grounded in a complete metabolic assessment (not just HbA1c), and aligned with the patient's goals and willingness to commit to sustained treatment.